Method
TrialSign uses internal technology to support evidence collection, normalization, consistency checks and traceability. Analytical conclusions and strategic interpretation remain subject to human review.
Workflow
01Decision framing
02Inclusion and exclusion criteria
03Evidence source plan
04Data cutoff
05Collection
06Normalization
07Deduplication and consistency checks
08Critical appraisal
09Claim-to-source mapping
10Confidence and uncertainty
11Human scientific review
12Client clarification
13Final quality gate
14Versioning and updates
Claim discipline
The report does not treat facts, synthesis, interpretation and recommendations as interchangeable. This prevents unsupported conclusions from appearing as source facts.
Registry, paper, label or public company material
Normalized evidence object with source IDs
Analyst statement with confidence and limits
Decision Book, Dossier or private workspace view
Statement types
Directly supported by a primary or public source.
A normalized combination of source facts.
Analyst reading of what the evidence implies.
A possible explanation that remains unconfirmed.
A missing, weak or unresolved evidence element.
A proposed follow-up question or diligence action.
Next step
Share the asset, target, indication or diligence question. TrialSign will identify the information needed to define a proportionate evidence plan.
Discuss a Diligence Question